Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI7352 in painful osteoarthritis of the knee
NCT02508155Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Dec 2020
- Modality
- Bispecific Antibodies
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of MEDI7352 in knee osteoarthritis (OA) (4 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability up to 84 days. Started Nov 2015; status: completed.
02
Drugs
MEDI7352
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02508155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508155.